Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.

Ocuphire Pharma, Inc.

Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing therapies for the treatment of inherited retinal diseases and other retinal and refractive disorders.

Metric
Company Name	Ocuphire Pharma, Inc.
Symbol	OCUP
MSH ID	COM:OCUPHIRE
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	14
Website	ocuphire.com
LinkedIn
Founders

Metric
Market Cap	42.77M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	19.05M
Revenue (LTM)
Revenue (NTM)
Gross Profit	19.04M
EBITDA	-10.56M
Operating Income	-10.56M
Net Income	-9.99M
EPS	-0.46
Diluted EPS	-0.46
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	1.00
Operating Profit Margin	-0.55
EBITDA Margin	-0.55
Net Profit Margin	-0.51
Return on Equity	-0.22
Return on Assets	-0.18
Return on Capital Employed	-0.21

COM:OCUPHIRE

Opus Genetics

Last Close

1.33

23/10 20:00

Market Cap

42.77M

Beta: -

Volume Today

675.97K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	1.85
P/B Ratio	1.07
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.82
EV Multiple	-4.83

Metric
Days Sales Outstanding	72.37
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle	59.86
Cash Conversion Cycle	6.19
Asset Turnover	0.37

Metric
Operating Cash Flow	-1.11M
Free Cash Flow	-1.11M
Cash Flow to Debt
Operating Cash Flow/Sales	-0.06
Free Cash Flow Yield	0.38

Metric
Cash & Equivalents	50.50M
Accounts Receivable	2.52M
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio	13.86
Quick Ratio	13.07

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.06
R&D to Revenue	0.30
SG&A to Revenue	0.19